Re: Combination therapy for Toxic Epidermal Necrolysis: It is time for anti-TNFa biologics comparison

Affiliations

¹ Division of Plastic and Reconstructive Surgery, Department of Surgery, LAC+USC Medical Center, Keck School of Medicine of the University of Southern California, United States.
² Division of Plastic and Reconstructive Surgery, Department of Surgery, LAC+USC Medical Center, Keck School of Medicine of the University of Southern California, United States. Electronic address: wgarner@med.usc.edu.

Comment

Christopher H Pham et al. Burns. 2020 Feb.

. 2020 Feb;46(1):245-246.

doi: 10.1016/j.burns.2019.11.011. Epub 2019 Dec 18.

¹ Division of Plastic and Reconstructive Surgery, Department of Surgery, LAC+USC Medical Center, Keck School of Medicine of the University of Southern California, United States.
² Division of Plastic and Reconstructive Surgery, Department of Surgery, LAC+USC Medical Center, Keck School of Medicine of the University of Southern California, United States. Electronic address: wgarner@med.usc.edu.

No abstract available

Comment on

Combination therapy: Etanercept and intravenous immunoglobulin for the acute treatment of Stevens-Johnson syndrome/toxic epidermal necrolysis.
Pham CH, Gillenwater TJ, Nagengast E, McCullough MC, Peng DH, Garner WL. Pham CH, et al. Burns. 2019 Nov;45(7):1634-1638. doi: 10.1016/j.burns.2018.12.018. Epub 2019 Aug 26. Burns. 2019. PMID: 31466921
Combination therapy for toxic epidermal necrolysis: It is time for anti-TNFa biologics comparison.
Gaitanis G, Bassukas ID. Gaitanis G, et al. Burns. 2020 Feb;46(1):244-245. doi: 10.1016/j.burns.2019.10.028. Epub 2019 Dec 13. Burns. 2020. PMID: 31843283 No abstract available.